Trials / Completed
CompletedNCT00002195
A Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected Patients
A Phase III Trial to Evaluate the Safety and Antiviral Efficacy of 141W94 in Combination With Retrovir and Epivir Compared to Retrovir and Epivir Alone in Patients With HIV Infection.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 290 (planned)
- Sponsor
- Glaxo Wellcome · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see if it is safe and effective to add 141W94 to an anti-HIV regimen that includes retrovir plus epivir.
Detailed description
This is a double-blind, placebo-controlled, two-arm study comparing treatment with a triple regimen consisting of 141W94, retrovir, and epivir and a double regimen consisting of retrovir and epivir.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Amprenavir | |
| DRUG | Lamivudine | |
| DRUG | Zidovudine |
Timeline
- First posted
- 2001-08-31
- Last updated
- 2005-06-24
Locations
9 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00002195. Inclusion in this directory is not an endorsement.